STOCKWATCH: Knights, daze and damp armor – Gilead, Vertex and impending debt
This article was originally published in Scrip
Executive Summary
In a week packed with third-quarter earnings drama it was not difficult to distinguish the heroes from the villains, although in the cool light of day, even some of the heroes had a few rust-spots in their armor. Closer scrutiny also reveals that some of the villainous knights from last week were being aided or hindered by their smaller squires.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.